skip to main content

SGLT2i Mechanism in HF — EECC MCQ

Instant feedback + full explanation. One question, done properly.

ModerateHeart FailureSGLT2i Mechanism in HFEECC

A 60-year-old man with HFrEF (LVEF 30%) and type 2 diabetes is started on dapagliflozin 10 mg. After 1 week, his HbA1c-lowering medication (gliclazide) is adjusted as his blood glucose has dropped. The patient asks whether dapagliflozin's cardiac benefit is related to its glucose-lowering effect. What is the correct explanation?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Cardiovascular benefit is independent of diabetic status

SGLT2 inhibitors (dapagliflozin, empagliflozin) improve HF outcomes independently of diabetes status — the DAPA-HF and EMPEROR-Reduced trials included approximately 55-60% non-diabetic patients with consistent benefit. Proposed mechanisms include: (1) osmotic natriuresis and reduced preload (without neurohormonal activation), (2) improved cardiac energetics (shift to ketone body utilisation as fuel), (3) reduced myocardial fibrosis and inflammation, (4) reduced sympathetic nervous system activity, and (5) improved endothelial function. The glycaemic effect is modest in non-diabetic patients (risk of hypoglycaemia is very low without insulin/SU). This class-agnostic benefit underpins the Class I recommendation across all EF ranges. Apply this conclusion only to the clinical circumstances stated, with appropriate specialist review, contraindication checks, shared decision-making and follow-up. Reassess if the physiology, treatment response or competing risk changes. The competing options would require a different haemodynamic profile, diagnosis, procedural indication or risk balance from the one described here.

Reference: ESC (2023): Focused Update on Heart Failure: https://bnf.nice.org.uk/